Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
-
* Corresponding author: Enrique Z Fisman zfisman@post.tau.ac.il
Cardiovascular Diabetology 2004, 3:10 doi:10.1186/1475-2840-3-10
Accesses
- Last 30 days: 42 accesses
- Last 365 days: 453 accesses
- All time: 9393 accesses
Cited by
BioMed Central: 2 citations
|
Review
Alexander Tenenbaum, Enrique Z Fisman, Michael Motro, Yehuda Adler Cardiovascular Diabetology 2006, 5:20 (26 September 2006) |
|
Editorial
Statins research unfinished saga: desirability versus feasibility Enrique Z Fisman, Yehuda Adler, Alexander Tenenbaum Cardiovascular Diabetology 2005, 4:8 (7 June 2005) |